Results 141 to 150 of about 3,884 (159)
Some of the next articles are maybe not open access.
Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 1975
Three E. coli strains representing strains from faeces of normal persons were established as antigenic test strains of two new O antigens, O162 and O163, and one new H antigen, H56.
I, ørskov +3 more
exaly +3 more sources
Three E. coli strains representing strains from faeces of normal persons were established as antigenic test strains of two new O antigens, O162 and O163, and one new H antigen, H56.
I, ørskov +3 more
exaly +3 more sources
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
Russian Chemical Bulletin, 2016
Aiming at creation of the chemical basis for serotyping of strains of Yersinia spp., we studied the O-specific polysaccharide (OPS) of Yersinia frederiksenii H56-36/81 belonging to serotype O:60. A branched polysaccharide was obtained by mild alkaline degradation of the lipopolysaccharide (LPS) isolated from bacterial cells by the phenol—water ...
O. V. Sizova +5 more
openaire +1 more source
Aiming at creation of the chemical basis for serotyping of strains of Yersinia spp., we studied the O-specific polysaccharide (OPS) of Yersinia frederiksenii H56-36/81 belonging to serotype O:60. A branched polysaccharide was obtained by mild alkaline degradation of the lipopolysaccharide (LPS) isolated from bacterial cells by the phenol—water ...
O. V. Sizova +5 more
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Journal of Infectious Diseases
Abstract Background H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB.
Dereck Tait +12 more
openaire +3 more sources
Abstract Background H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB.
Dereck Tait +12 more
openaire +3 more sources
Aviation, space, and environmental medicine, 1994
A case is presented which involves a fighter pilot with anxiety disorder and in-flight panic attacks. The initial presentation, clinical course, evaluation, and aeromedical disposition are all discussed.
L M, Johnson, F E, Carpenter
openaire +1 more source
A case is presented which involves a fighter pilot with anxiety disorder and in-flight panic attacks. The initial presentation, clinical course, evaluation, and aeromedical disposition are all discussed.
L M, Johnson, F E, Carpenter
openaire +1 more source
Lancet Infectious Diseases, The
People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown.In a double-blind, randomised, placebo-controlled, phase 2b trial in South Africa (five clinical trial ...
Julia Noble +2 more
exaly +3 more sources
People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown.In a double-blind, randomised, placebo-controlled, phase 2b trial in South Africa (five clinical trial ...
Julia Noble +2 more
exaly +3 more sources
H56 Huntington disease as a risk factor for offspring’s well-being
H: Clinical care and clinical services, 2022Sabrina Maffi +5 more
openaire +1 more source